Structure activity relationship of antiproliferative agents using multiple linear regression

Chemical Biology and Drug Design

Volumn 74, Issue 3, 2009, Pages 309-316

  Winfield, Leyte L ^a   Inniss, Tasha R ^a   Smith, Dayle M ^b  

^a SPELMAN COLLEGE   (United States)

^b WHITMAN COLLEGE   (United States)

Author keywords

Anticancer; Antiproliferative; Benzimidazole; PC3; Pharmacophore; Pyrazole; QSAR; Regression

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2; PYRAZOLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MULTIPLE LINEAR REGRESSION ANALYSIS; PKA; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; LINEAR MODELS; PYRAZOLES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 68949219637     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2009.00863.x     Document Type: Article

References (21)

1. American Cancer Society (2008) Cancer Facts and Figures 2007-2008. Atlanta, GA : American Cancer Society.
2. Sakr W., Gignon D., Haas G. (1998) Pathology of premalignant lesions and carcinoma of the prostate in African-American men. Semin Urol Oncol 16 : 214 220.
3. Sanchez-Ortiz R., Troncoso P., Babaian R., Lloreta J., Johnston D., Pettaway C. (2006) White men African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched. Cancer 107 : 75 82.
4. Solomon S., Wittes J., Finn P., Fowler R., Viner J., Bertagnolli M., Arber N. et al. (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials. Circulation 16 : 2104 2113.
5. Mehar A., Macanas-Pirard P., Mizokami A., Takahashi Y., Kass G., Coley H. (2008) The effects of cyclooxygenase-2 expression in prostate cancer cells: modulation of response to cytotoxic agents. J Pharmacol Exp Ther 324 : 1181 1187.
6. Cho S.-J., Kim N., Kim J., Jung H., Song I. (2007) The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci 52 : 1713 1721.
7. Madan R., Xia Q., Chang V., Oriscello R., Kasimis B. (2007) A retrospective analysis of cardiovascular morbidity in metastatic hormone-refractory prostate cancer patients on high doses of the selective COX-2 inhibitor celecoxib. Expert Opin Pharmacother 8 : 1425 1431.
8. Abraham N.S., El-Serag H.B., Hartman C., Richardson P., Deswal A. (2007) Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Alimentary Pharmacol Ther 25 : 913 924.
9. Abadi A., Eissa A., Hassan G. (2003) Synthesis of novel 1,3,4-trisubstituted pyrazole derivatives and their evaluation as antitumor and antiangiogenic agents. Chem Pharm Bull 51 : 838 844.
10. Cen L., Hsieh F.-C., Lin H.-J., Chen C.-S., Qualman S.J., Lin J. (2007) PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound. Brit J Cancer 97 : 785 791.
11. Zhang S., Suvannasankha A., Crean C., White V., Johnson A., Chen C.-S., Farag S. (2007) OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms. Clin Cancer Res 13 : 4750 4758.
12. Crowder R., Ellis M. (2005) Treating breast cancer through novel inhibitors of the phosphatidylinositol 3′-kinase pathway. Breast Cancer Res 7 : 212 214.
13. Wang Y.-C., Kulp S., Wang D., Yang C.-C., Sargeant A., Hung J.-H., Kashida Y., Yamaguchi M., Chang G.-D., Chen C.-S. (2008) Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res 68 : 2820 2830.
14. Weng S.-C., Kashida Y., Kulp S., Wang D., Brueggemeier R., Shapiro C., Chen C.-S. (2008) Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor. Mol Cancer Ther 7 : 800 808.
15. Zhu J., Huang J., Tseng P., Yang Y., Fowble J., Shiau C., Shaw Y., Kulp S., Chen C. (2004) From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 64 : 4309 4318.
16. Reddy M., Su C.-R., Chiou W.-F., Liu Y.-N., Chen R., Bastow K., Lee K.-H., Wua T.-S. (2008) Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as cytotoxic agents. Bioorg Med Chem 16 : 7358 7370.
17. Zhang Y., Chen Z., Lou Y., Yu Y. (2009) 2,3-Disubstituted 8-arylamino-3H-imidazo[4,5-g]quinazolines: a novel class of antitumor agents. Eur J Med Chem 44 : 448 452.
18. Jain H., Zhang C., Zhou S., Zhou H. et al. (2008) Synthesis and structure-activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein. Bioorg Med Chem 16 : 4626 4651.
19. Martínez R., Arzate M., Ramírez-Apan Ma T. (2009) Synthesis and cytotoxic activity of new azepino[3′,4′:4,5]pyrrolo[2,1- α]isoquinolin-12-ones. Bioorg Med Chem 17 : 1849 1856.
20. Bézière N., Goossens L., Pommery J., Vezin H., Touati N., Hénichart J.-P., Pommery N. (2008) New NSAIDs-NO hybrid molecules with antiproliferative properties on human prostatic cancer cell lines. Bioorg Med Chem Lett 8 : 4655 4657.
21. Winfield L., Smith D., Halemano K., Leggett C. (2008) A preliminary assessment of the structure-activity relationship of benzimidazole-based anti-proliferative agents. Lett Drug Des Discov 5 : 369 376.